Salmeterol Xinafoate

General information about the Salmeterol Xinafoate active pharmaceutical ingredient

Salmeterol Xinafoate as active pharmaceutical ingredient (API) is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol Xinafoate works on bronchial smooth muscle causing an increase in the expansion of a bronchus or bronchial tubes. Salmeterol Xinafoate is found in combination with compounds such as beclometasone dipropionate(hyperlink) or fluticasone propionate (hyperlink) in the treatment of asthma. Salmeterol Xinafoate is mainly found as aerosol and powder for inhalation.

Axplora manufactures Salmeterol Xinafoate API

Salmeterol Xinafoate API is manufactured in cGMP by Axplora via chemical synthesis from early stage starting material. Salmeterol Xinafoate API is produced by Farmabios, our EUGMP, USFDA and PMDA approved manufacturing site with legal seat in Gropello Cairoli, Italy. Farmabios’ expertise is to make and handle with steroids, niche hormones, and highly potent active pharmaceutical ingredient (HPAPI), including cytotoxic drugs. Salmeterol Xinafoate API is commercially available in multiple micronized grades specifically designed around various formulation requirements. Salmeterol Xinafoate API customized particle size distribution (PSD) grades, including post milling conditioning, and tailor-made packaging solutions are available upon request. Feel free to contact us if you need any additional information about Salmeterol Xinafoate API.